Kanbour Aladdin, Salih Faroug, Abualainin Wafa, Abdelrazek Mohamed, Szabados Lajos, Al-Bozom Issam, Omar Nabil E
Medical Oncology Department, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
Solid Tumor Section, Molecular Genetics Laboratory, Diagnostic Genomic Division, Department of Laboratory Medicine and Pathology, Hamad Medical Corporation, Doha, Qatar.
Onco Targets Ther. 2022 Jun 14;15:659-667. doi: 10.2147/OTT.S336012. eCollection 2022.
Leptomeningeal carcinomatosis (LMC) is a known sequel of metastatic lung cancer and its treatment is challenging. Nevertheless, treatment options for LMC due to metastatic epidermal growth factor receptor-mutant (-mutant) lung adenocarcinoma are expanding. We present a 52-year-old male patient with metastatic non-small-cell lung cancer (NSCLC). The patient was found to have L858R mutation in exon 21 of the EGFR gene. He was initially treated with erlotinib, followed by afatinib/cetuximab, followed by chemotherapy. Thereafter, his disease progressed to LMC. Although tissue biopsy did not show T790M-mutation, osimertinib (160 mg once daily) promptly induced clinical and radiological response that continued for five months. High dose pulsed erlotinib (1500 mg weekly) improved his quality of life and extended his survival for a further four months.
软脑膜癌病（LMC）是转移性肺癌已知的一种后遗症，其治疗具有挑战性。然而，由转移性表皮生长因子受体突变（-突变）肺腺癌导致的LMC的治疗选择正在不断增加。我们报告一名52岁的男性转移性非小细胞肺癌（NSCLC）患者。该患者被发现表皮生长因子受体（EGFR）基因第21外显子存在L858R突变。他最初接受厄洛替尼治疗，随后使用阿法替尼/西妥昔单抗，之后进行化疗。此后，他的病情进展为LMC。尽管组织活检未显示T790M突变，但奥希替尼（每日一次，160毫克）迅速引发了临床和影像学反应，这种反应持续了五个月。高剂量脉冲式厄洛替尼（每周1500毫克）改善了他的生活质量，并将其生存期又延长了四个月。
